Subscribe
Wirestock Creators / Shutterstock.com
19 November 2024NewsAmericasSarah Speight

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

US Supreme Court blocks bid to overturn lower court ruling | District court found in 2023 that the generic would infringe patents owned by a Bausch subsidiary | Blockbuster drug Xifaxan is used to treat IBS with diarrhoea, and a liver-related brain disorder.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Setback for Alvogen in approval bid for IBS generic
2 November 2023   District court denies Norwich’s motion to compel FDA to grant approval for its version of popular IBS medication | Court also grants summary judgment in favour of FDA and Norwich’s competitor.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Generics
Setback for Alvogen in approval bid for IBS generic
2 November 2023   District court denies Norwich’s motion to compel FDA to grant approval for its version of popular IBS medication | Court also grants summary judgment in favour of FDA and Norwich’s competitor.

More on this story

Generics
Setback for Alvogen in approval bid for IBS generic
2 November 2023   District court denies Norwich’s motion to compel FDA to grant approval for its version of popular IBS medication | Court also grants summary judgment in favour of FDA and Norwich’s competitor.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages